Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Scientific Acquires IntegenX

NEW YORK (GenomeWeb) – Thermo Fisher Scientific said on Friday that it has acquired forensic DNA testing firm IntegenX for an undisclosed amount.

IntegenX, headquartered in Pleasanton, California, has been developing rapid DNA testing technology for human identification for use in forensics and law enforcement. In 2015, the company launched the RapidHit ID System, which allows users to profile individuals from buccal swabs in less than two hours using short tandem repeat (STR) chemistries sold by Thermo Fisher. In addition, it sells the RapidHIT System, its first-generation STR-based human identification system that is also compatible with Thermo Fisher's STR kits.

IntegenX's technology is currently used in government laboratories of 17 countries to generate forensic DNA profiles.

According to Thermo Fisher, IntegenX complements and enhances its existing human identification product portfolio, including reagents, qPCR systems, and capillary electrophoresis systems.

"The development of rapid DNA technology provides law enforcement with the ability to generate results while a suspect is still in custody," said Rosy Lee, vice president of human identification at Thermo Fisher, in a statement. The increased demand for such testing from law enforcement agencies, she said, "aligns with our strategy to expand our leadership position in the human identification market."

"Combining our market-leading technologies with Thermo Fisher's scale and depth of capabilities will benefit both our customers and our employees," said Robert Schueren, president and CEO of IntegenX, in a statement.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.